Allelica, Inc

We are thrilled to announce that we are joining forces with Labcorp to make polygenic risk score and precision risk assessments accessible to patients of all ancestral backgrounds. This brings us one step closer to our goal of reducing disease burden with better medicine. Read the full announcement: https://lnkd.in/dN5MWFda

Interested in learning how you can implement precision medicine for common disease? Join us next Wednesday, October 9th for an insightful webinar titled "Unlocking the Genetic Code: Harnessing the Power of Human Genotyping Arrays for Accurate Polygenic Risk Score Analysis". Alongside leaders in genomic technology, Allelica CEO, Giordano Bottà PhD, will be discussing polygenic risk score (PRS) for cardiovascular disease and its power to improve health outcomes and disease management. Register here: https://lnkd.in/djPaXJpr Thermo Fisher Scientific Monash University

Excited to be part of the Southern California Symposium on Polygenic Risk Scores today! Alongside leading genomics experts from Cedars-Sinai, MIT, Georgia Tech and Harvard, Allelica scientist, Scott Kulm PhD, will be presenting on the crucial role of ancestry in equitable PRS implementation. #genomics #genetics #polygenic #PRS #healthequity Information on the event can be found here: https://lnkd.in/dv6YpKcx

If you are a pharmaceutical company or biotech running clinical trials, have you thought about how genomic data can be used to make them cheaper, quicker and more efficient? From identifying people who respond better to therapeutics to saving failed clinical trials through retrospective analyses, genomic information -- harnessed through Polygenic Risk Scores (PRS) -- have a clear role to play in the future of pharmaceutical developments. Read more in Allelica, Inc's article on how PRS can super-power your clinical trials and get in touch with us to learn more about how our tools can help you perform better clinical trials, whatever stage your trial might be at. #polygenicriskscores #pharma #genomics https://lnkd.in/e9UfEg2k

Are you considering all available risk factors when deciding whether to prescribe lipid-lowering therapies? Are you confident you're identifying all the high-risk individuals who come to your office? Statins are recommended for individuals who have a >10% chance of CVD in the next ten years who also have a risk enhancing factor. Risk enhancers include things like: - Diabetes / 2-4 times increase in risk - Dyslipidemia / 2 times increase - Hypertension / 1.5 times increase - Smoking / 2 times increase But there is another key risk factor that’s missing from this list. Polygenic risk scores. PRSs identify individuals with an equivalent increase in CVD risk to these risk enhancers. Genetic risk from PRSs is orthogonal to these other risk factors meaning that without a PRS test, patients at high risk are routinely being missed. They are flying under the radar and are not getting the help they need to mitigate this risk. Allelica, Inc's multi-ancestry PRSs for coronary artery disease identify a significant proportion of people (between 25% and 12% depending on ancestry) who have at least twice the risk of people without this risk factor. Given their established effect on CVD risk -- and their prevalence in the population -- these high PRS can be used as risk enhancers. Knowing your patient’s PRS provides actionable insight into your CVD risk and is a critical piece of information that can help patients and their doctors work out how to best to drive down their 10 year CVD risk and avoid future ill health through preventative measures. Get in touch to find out how we can get you quickly set up to implement Allelica, Inc's PRSs and join others who are using this crucial piece of information to enhance CVD prevention in their clinical practice. #polygenicriskscores #prevention #cardiovasculardisease https://lnkd.in/eQGrBa4W https://lnkd.in/evs7y7XY https://lnkd.in/edmzmz5K

Pathogenic mutations in established breast cancer susceptibilty genes increase a woman's risk of disease, but are only present in a small fraction of the population: 0.1-1% per gene; or <5% across the top 8 genes combined. Moreover, the vast majority of breast cancer cases (80-85%) occur without one of these single, identifiable high-risk genetic mutations. As the average lifetime risk of breast cancer in women is around 12.5%, population based analyses have led to the following lifetime / relative risk estimates for mutation carriers, here shown for a selection of genes that are reported in the NCCN Guidelines*: BRCA1: 45-65% / ~5+ times increased risk BRCA2: 35-55% / ~4-5 times increased risk PALB2: 40-60% / ~4 times increased risk CHEK2: 20-40% / ~2-3 times increased risk ATM: 20-30% / ~2.5 times increased risk What about polygenic risk scores? Using Allelica, Inc's latest multi-ancestry PRSs, we identify a 3-fold increase in relative risk for the 5% of women with the highest PRS values. That is: High Allelica Breast Cancer PRS: 25-35% lifetime risk / ~3 times increased risk So 1 in 20 women have high genetic risk of breast cancer (equivalent to carriers of mutations in all but the most penetrant susceptibility genes) that can only be identified with a PRS test. An even larger number of women (10-20%) have 2 times the average population risk of breast cancer because of a high PRS. This means that a significant proportion of women at high genetic risk of breast cancer can be found with a PRS test. Allelica, Inc helps providers across the world use PRS to identify these women. Get in touch with us if you are interested in understanding how we can quickly set you up to provide this test to your patients, allowing you to identify more women at high risk so that appropriate risk mitigation can be put in place to help cancer to be caught as early as possible and improve patient outcomes. #polygenicriskscores #prevention #breastcancer *NB: estimates from the general population for the increased risk of carriers of mutations in some of these genes is actually likely to be lower than those reported in the NCCN guildelines, see the link below for further details. https://lnkd.in/dTHuRgv

Family history is a well established risk factor for breast cancer, increasing a woman's risk by around 2 times compared to women without family history. But did you know that breast cancer polygenic risk scores (PRSs) can also identify women at 2 times (and even higher) increased risk of breast cancer, and that this genetic risk is largely independent of family history? (https://lnkd.in/em2T5CUE) As physicians routinely ask about family history when assessing a patient's breast cancer risk, shouldn't they also know their PRS? What do you think? If you're interested in implementing multi-ancestry PRSs for breast cancer in your clinic, get in touch Allelica, Inc

???? Up to 1 in 3 heart attacks happen in people with no clear clinical risk factors for cardiovascular disease? ? This means that a significant proportion of people who are at risk of heart attack are invisible to risk prediction based on clinical risk factors alone. ? Read Allelica, Inc's latest article on PRSs and cardiovascular disease to learn more about the benefits of incorporating PRS tests into cardiovascular disease prevention efforts. https://lnkd.in/erDetat9

Catching breast cancer early when it is localized is crucial, as the five-year relative survival rate is 99%. But how can genetics be used to identify more women at risk of breast cancer? ? Check out Allelica, Inc’s new article describing how PRSs are used to mitigate breast cancer disease risk, including: - How primary care physicians can integrate this information into standard clinical breast cancer risk assessments - How integrating PRSs into established risk models like the Tyrer-Cuzick and BOADICEA leads to more accurate risk assessments - How risk conferred by high PRSs is equivalent to risk of disease from rare pathogenic variants If you are interested in using clinical practice, get in touch! https://lnkd.in/g2fQVhvW

???? Atherosclerosis is the buildup of fats, cholesterol and other substances in and on the artery walls. These deposits are called plaques and are a major cause of heart disease. ? But, did you know that people build?these plaques differently, even in the presence of similar levels of LDL-cholesterol? This is in part explained by the interaction between genetics -- measured with polygenic risk scores -- and cholesterol in the blood. Cholesterol does not affect everyone in the same way. Learn more about the science behind this interaction and how clinicians are using PRSs to identify people at increased risk of cardiovascular disease in Allelica, Inc's latest article on PRSs and cardiovasular disease. https://lnkd.in/erDetat9